Hyloris Pharmaceuticals

{
  "stage": null,
  "notary": {
    "name": "Tim CARNEWAL",
    "firm_city": null,
    "firm_name": "Berquin Notaires",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2026-04-08",
    "filing_date": "2026-04-03",
    "act_kind_objet": "DIVERS"
  },
  "decision": {
    "body": "raad_van_bestuur",
    "act_date": "2026-03-30",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "other",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0674.494.151",
        "name": "Hyloris Pharmaceuticals",
        "role": "other",
        "address": "Boulevard de Patience et Beaujonc 3 bte 1, 4000 Li\u00E8ge",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "7:180",
      "7:191",
      "7:198",
      "6"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": 250000,
    "real_estate_included": false,
    "patrimony_description": "\u00C9mission de 250 000 Stock Option Warrants 2026, donnant droit \u00E0 souscrire de nouvelles actions de la soci\u00E9t\u00E9 Hyloris Pharmaceuticals. L\u0027augmentation du capital est conditionnelle \u00E0 l\u0027exercice effectif de ces warrants.",
    "equity_transferred_eur": null,
    "accounting_effective_date": null
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "Hyloris Pharmaceuticals",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Tim CARNEWAL",
    "org_rep_person_name": null
  },
  "summary_narrative": "Le conseil d\u0027administration de Hyloris Pharmaceuticals SA a approuv\u00E9 le Plan Warrants 2026, d\u00E9cid\u00E9 l\u0027\u00E9mission de 250 000 Stock Option Warrants 2026 \u00E0 titre gratuit, avec une dur\u00E9e de validit\u00E9 de six ans, et a autoris\u00E9 l\u0027augmentation du capital social en cas d\u0027exercice des warrants. Le prix d\u0027exercice sera d\u00E9termin\u00E9 selon le cours moyen des actions sur les 30 jours pr\u00E9c\u00E9dant l\u0027offre. Le conseil a \u00E9galement d\u00E9l\u00E9gu\u00E9 des pouvoirs \u00E0 son comit\u00E9 de r\u00E9mun\u00E9ration et \u00E0 ses administrateurs pour g\u00E9rer les formalit\u00E9s li\u00E9es \u00E0 l\u0027attribution et \u00E0 l\u0027exercice des warrants.",
  "co_filed_documents": [
    "une exp\u00E9dition du proc\u00E8s-verbal",
    "une procuration",
    "le Plan Warrants",
    "le texte coordonn\u00E9 des statuts",
    "le rapport du conseil d\u2019administration",
    "le rapport du commissaire r\u00E9dig\u00E9 en application de l\u2019article 7:198 juncto les articles 7:180 et 7:191 du CSA"
  ],
  "detected_real_type": "other",
  "referenced_correction": null,
  "should_reroute_to_category": "capital_shares"
}

{
  "events": [
    {
      "kind": "commissaris_out",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Thomas JACOBSEN",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0552806859",
        "name": "Jacobsen Management SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2025-11-18",
      "evidence_quote": "Le conseil d\u0027administration prend acte et, dans la mesure n\u00E9cessaire, accepte la d\u00E9mission de Jacobsen Management SRL, repr\u00E9sent\u00E9e par son repr\u00E9sentant permanent M. Thomas JACOBSEN, en tant que Co-CEO, avec effet imm\u00E9diat."
    },
    {
      "kind": "commissaris_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Stijn VAN ROMPAY",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0552806859",
        "name": "SVR Management SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2025-11-19",
      "evidence_quote": "Le conseil d\u0027administration confirme qu\u0027\u00E0 partir du 19 novembre 2025, SVR Management SRL [dont le si\u00E8ge est sis \u00E0 Vlieghavenlaan 24, 3140 Keerbergen (Belgique), inscrite \u00E0 la Banque-Carrefour des Entreprises sous le num\u00E9ro 0552.806.859 (RPM Louvain)], repr\u00E9sent\u00E9e par son repr\u00E9sentant permanent M. St"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Marc FOIDART",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "L\u0027Assembl\u00E9e prend acte de la d\u00E9mission de M. Marc FOIDART, M. Vincent VAN DESSEL et Mme Revital RATTENBACH de leurs fonctions d\u0027administrateurs ind\u00E9pendants de la Soci\u00E9t\u00E9, avec effet \u00E0 compter de la cl\u00F4ture de l\u0027Assembl\u00E9e Annuelle appel\u00E9e \u00E0 se prononcer sur les comptes annuels de l\u0027exercice se termi"
    },
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Vincent VAN DESSEL",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "L\u0027Assembl\u00E9e prend acte de la d\u00E9mission de M. Marc FOIDART, M. Vincent VAN DESSEL et Mme Revital RATTENBACH de leurs fonctions d\u0027administrateurs ind\u00E9pendants de la Soci\u00E9t\u00E9, avec effet \u00E0 compter de la cl\u00F4ture de l\u0027Assembl\u00E9e Annuelle appel\u00E9e \u00E0 se prononcer sur les comptes annuels de l\u0027exercice se termi"
    },
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Revital RATTENBACH",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "L\u0027Assembl\u00E9e prend acte de la d\u00E9mission de M. Marc FOIDART, M. Vincent VAN DESSEL et Mme Revital RATTENBACH de leurs fonctions d\u0027administrateurs ind\u00E9pendants de la Soci\u00E9t\u00E9, avec effet \u00E0 compter de la cl\u00F4ture de l\u0027Assembl\u00E9e Annuelle appel\u00E9e \u00E0 se prononcer sur les comptes annuels de l\u0027exercice se termi"
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Mme M\u00E9lanie MESTDAGT",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "Biofinance Consulting BV",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "L\u0027Assembl\u00E9e d\u00E9cide de nommer: - Biofinance Consulting BV, repr\u00E9sent\u00E9e par Mme M\u00E9lanie MESTDAGT, - Sybefica Invest BV, repr\u00E9sent\u00E9e par M. Vincent VAN DESSEL, et - IRYL Partners SAS, repr\u00E9sent\u00E9e par Mme Revital RATTENBACH, en tant qu\u0027administrateurs ind\u00E9pendants pour un mandat de trois (3) ans, jusqu\u0027"
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "M. Vincent VAN DESSEL",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "Sybefica Invest BV",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "L\u0027Assembl\u00E9e d\u00E9cide de nommer: - Biofinance Consulting BV, repr\u00E9sent\u00E9e par Mme M\u00E9lanie MESTDAGT, - Sybefica Invest BV, repr\u00E9sent\u00E9e par M. Vincent VAN DESSEL, et - IRYL Partners SAS, repr\u00E9sent\u00E9e par Mme Revital RATTENBACH, en tant qu\u0027administrateurs ind\u00E9pendants pour un mandat de trois (3) ans, jusqu\u0027"
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Mme Revital RATTENBACH",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "IRYL Partners SAS",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "L\u0027Assembl\u00E9e d\u00E9cide de nommer: - Biofinance Consulting BV, repr\u00E9sent\u00E9e par Mme M\u00E9lanie MESTDAGT, - Sybefica Invest BV, repr\u00E9sent\u00E9e par M. Vincent VAN DESSEL, et - IRYL Partners SAS, repr\u00E9sent\u00E9e par Mme Revital RATTENBACH, en tant qu\u0027administrateurs ind\u00E9pendants pour un mandat de trois (3) ans, jusqu\u0027"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "commissaris_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Christophe PELZER",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0431088289",
        "name": "BDO BEDRIJFSREVISOREN BV / BDO R\u00C9VISEURS D\u0027ENTREPRISES SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "L\u0027Assembl\u00E9e d\u00E9cide de nommer BDO BEDRIJFSREVISOREN BV I BDO R\u00C9VISEURS D\u0027ENTREPRISES SRL, repr\u00E9sent\u00E9e par M. Christophe PELZER, ayant son si\u00E8ge social sis Da Vincilaan 9, BO\u00CETE 6, 1935 ZAVENTEM, Belgique, et immatricul\u00E9e sous le num\u00E9ro d\u0027entreprise BE 0431.088.289, en qualit\u00E9 de commissaire aux compt"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "commissaris_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Tanguy Legein",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "KPMG R\u00E9viseurs d\u0027Entreprises SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2024-04-23",
      "evidence_quote": "L\u0027organe d\u0027administration de la soci\u00E9t\u00E9 KPMG R\u00E9viseurs d\u0027Entreprises SRL, commissaire de Hyloris Pharmaceuticals SA, a d\u00E9cid\u00E9 de nommer Monsieur Tanguy Legein en tant que repr\u00E9sentant permanent de KPMG R\u00E9viseurs d\u0027Entreprises SRL \u00E0 partir du 23 avril 2024."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "stage": null,
  "notary": {
    "name": "Tim CARNEWAL",
    "firm_city": null,
    "firm_name": "Berquin Notaires",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2025-01-30",
    "filing_date": "2025-01-28",
    "act_kind_objet": "DIVERS"
  },
  "decision": {
    "body": "raad_van_bestuur",
    "act_date": "2025-01-20",
    "unanimous": true
  },
  "conversion": null,
  "detected_kind": "other",
  "report_waiver": null,
  "restructuring": {
    "parties": [],
    "exchange_ratio": null,
    "legal_articles": [
      "7:179",
      "7:180",
      "7:191",
      "7:193"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "Aucun transfert de patrimoine n\u0027est effectu\u00E9. L\u0027acte concerne l\u0027\u00E9mission de Stock Option Warrants 2025 et l\u0027annulation de Warrants ant\u00E9rieurs.",
    "equity_transferred_eur": null,
    "accounting_effective_date": null
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "Hyloris Pharmaceuticals",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "HERAULT",
    "person_name": null,
    "org_rep_person_name": "Koenraad Van der Elst"
  },
  "summary_narrative": "Le conseil d\u0027administration de Hyloris Pharmaceuticals SA a d\u00E9cid\u00E9 \u00E0 l\u0027unanimit\u00E9 d\u0027annuler 119.500 Stock Option Warrants 2020 et 95.000 Stock Option Warrants 2022, suite \u00E0 la renonciation explicite des titulaires. Il a \u00E9galement approuv\u00E9 l\u0027\u00E9mission de 650.000 Stock Option Warrants 2025, avec possibilit\u00E9 d\u0027augmentation du capital \u00E0 l\u0027exercice des Warrants. Des pouvoirs ont \u00E9t\u00E9 d\u00E9l\u00E9gu\u00E9s \u00E0 des administrateurs et \u00E0 la soci\u00E9t\u00E9 HERAULT pour mener \u00E0 bien les formalit\u00E9s administratives et notariales.",
  "co_filed_documents": [
    "proc\u00E8s-verbal",
    "quinze procurations",
    "Plan Warrants 2025",
    "rapport du conseil d\u0027administration",
    "texte coordonn\u00E9 des statuts"
  ],
  "detected_real_type": "other",
  "referenced_correction": null,
  "should_reroute_to_category": "capital_shares"
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Chris Buyse",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0674494151",
        "name": "Pienter Jan SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2024-12-06",
      "evidence_quote": "L\u0027Assembl\u00E9e prend connaissance de, et, pour autant que de besoin, accepte, la d\u00E9mission de Pienter Jan SRL, repr\u00E9sent\u00E9e par M. Chris Buyse, avec effet \u00E0 partir de la cl\u00F4ture de l\u0027Assembl\u00E9e Annuelle qui statuera sur les comptes annuels de l\u0027exercice clos le 31 d\u00E9cembre 2023."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Stijn van Rompay",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0674494151",
        "name": "SVR Management SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "Sur recommandation du comit\u00E9 de nomination et de r\u00E9mun\u00E9ration, [...] d\u00E9cide de (re)nommer les administrateurs suivants pour une dur\u00E9e de 4 ans, jusqu\u0027\u00E0 la cl\u00F4ture de l\u0027assembl\u00E9e g\u00E9n\u00E9rale annuelle qui se tiendra en 2028: (v) SVR Management SRL, repr\u00E9sent\u00E9e par M. Stijn van Rompay,"
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Thomas Jacobsen",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0674494151",
        "name": "Jacobsen Management SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "Sur recommandation du comit\u00E9 de nomination et de r\u00E9mun\u00E9ration, [...] d\u00E9cide de (re)nommer les administrateurs suivants pour une dur\u00E9e de 4 ans, jusqu\u0027\u00E0 la cl\u00F4ture de l\u0027assembl\u00E9e g\u00E9n\u00E9rale annuelle qui se tiendra en 2028: (vi) Jacobsen Management SRL, repr\u00E9sent\u00E9e par M. Thomas Jacobsen,"
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Leon Van Rompay",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0674494151",
        "name": "Van Rompay Management SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "Sur recommandation du comit\u00E9 de nomination et de r\u00E9mun\u00E9ration, [...] d\u00E9cide de (re)nommer les administrateurs suivants pour une dur\u00E9e de 4 ans, jusqu\u0027\u00E0 la cl\u00F4ture de l\u0027assembl\u00E9e g\u00E9n\u00E9rale annuelle qui se tiendra en 2028: (vii) Van Rompay Management SRL, repr\u00E9sent\u00E9e par M. Leon Van Rompay,"
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Stefan Yee",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "Sur recommandation du comit\u00E9 de nomination et de r\u00E9mun\u00E9ration, [...] d\u00E9cide de (re)nommer les administrateurs suivants pour une dur\u00E9e de 4 ans, jusqu\u0027\u00E0 la cl\u00F4ture de l\u0027assembl\u00E9e g\u00E9n\u00E9rale annuelle qui se tiendra en 2028: (viii) M. Stefan Yee."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Revital Rattenbach",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "En outre, sur recommandation du comit\u00E9 de nomination et de r\u00E9mun\u00E9ration, [...] d\u00E9cide de nommer Mme Revital Rattenbach, M. Marc Foidart et M. Vincent Van Dessel en tant qu\u0027administratrice et administrateurs ind\u00E9pendant(e)s pour une dur\u00E9e de 4 ans, jusqu\u0027\u00E0 la cl\u00F4ture de l\u0027assembl\u00E9e g\u00E9n\u00E9rale annuelle "
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Marc Foidart",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "En outre, sur recommandation du comit\u00E9 de nomination et de r\u00E9mun\u00E9ration, [...] d\u00E9cide de nommer Mme Revital Rattenbach, M. Marc Foidart et M. Vincent Van Dessel en tant qu\u0027administratrice et administrateurs ind\u00E9pendant(e)s pour une dur\u00E9e de 4 ans, jusqu\u0027\u00E0 la cl\u00F4ture de l\u0027assembl\u00E9e g\u00E9n\u00E9rale annuelle "
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Vincent Van Dessel",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "En outre, sur recommandation du comit\u00E9 de nomination et de r\u00E9mun\u00E9ration, [...] d\u00E9cide de nommer Mme Revital Rattenbach, M. Marc Foidart et M. Vincent Van Dessel en tant qu\u0027administratrice et administrateurs ind\u00E9pendant(e)s pour une dur\u00E9e de 4 ans, jusqu\u0027\u00E0 la cl\u00F4ture de l\u0027assembl\u00E9e g\u00E9n\u00E9rale annuelle "
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "gedelegeerd_bestuurder",
      "person": {
        "rrn": null,
        "name": "Thomas Jacobsen",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "Jacobsen Management SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2024-07-26",
      "evidence_quote": "Par la pr\u00E9sente, les administrateurs : 1. d\u00E9cident de nommer Jacobsen Management SRL (repr\u00E9sent\u00E9e de fa\u00E7on permanente par M. Thomas Jacobsen) en tant qu\u0027administrateur d\u00E9l\u00E9gu\u00E9 de la Soci\u00E9t\u00E9, charg\u00E9 des pouvoirs de la gestion journali\u00E8re et portant le titre de co-CEO, \u00E0 c\u00F4t\u00E9 de SVR Management SRL (re"
    },
    {
      "kind": "director_renew",
      "role": "gedelegeerd_bestuurder",
      "person": {
        "rrn": null,
        "name": "Stijn Van Rompay",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "SVR Management SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2024-07-26",
      "evidence_quote": "Par la pr\u00E9sente, les administrateurs : 1. d\u00E9cident de nommer Jacobsen Management SRL (repr\u00E9sent\u00E9e de fa\u00E7on permanente par M. Thomas Jacobsen) en tant qu\u0027administrateur d\u00E9l\u00E9gu\u00E9 de la Soci\u00E9t\u00E9, charg\u00E9 des pouvoirs de la gestion journali\u00E8re et portant le titre de co-CEO, \u00E0 c\u00F4t\u00E9 de SVR Management SRL (re"
    },
    {
      "kind": "director_renew",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Carolyn Myers",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2024-07-26",
      "evidence_quote": "3. d\u00E9cident que Mme Carolyn Myers sera d\u00E9sormais consid\u00E9r\u00E9e comme un administrateur non ex\u00E9cutif, mais ne plus comme un administrateur ind\u00E9pendant de la Soci\u00E9t\u00E9, pour le reste de son mandat"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2024-07-01",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  },
  "signature_regime": null,
  "special_mandates": [
    {
      "quote": "Le pr\u00E9sident soumet \u00E0 l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire la proposition d\u0027accorder des pouvoirs sp\u00E9ciaux \u00E0 M. Koenraad Van der Elst, Chief Legal Officer de la Soci\u00E9t\u00E9, et \u00E0 Mme. Gis\u00E8le Rosselle, M. C\u00E9deric Devroey, Mme. Marie-Elisabeth Dubois et M. Th\u00E9otime Liesenborghs, tous avocats au sein du cabinet Strelia, dont le si\u00E8ge est situ\u00E9 Rue Royale 145, 1000 Bruxelles, Belgique. Ces pouvoirs sp\u00E9ciaux permettent \u00E0 chacun d\u0027eux d\u0027agir individuellement et d\u0027avoir le pouvoir de subd\u00E9l\u00E9guer pour accomplir au nom et pour le compte de la Soci\u00E9t\u00E9 toutes les formalit\u00E9s relatives aux obligations de publicit\u00E9 impos\u00E9es par la loi concernant les r\u00E9solutions adopt\u00E9es lors de l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire et, plus particuli\u00E8rement, \u00E0 la publication d\u0027un extrait du pr\u00E9sent proc\u00E8s-verbal aux Annexes du Moniteur belge et, g\u00E9n\u00E9ralement, pour accomplir toutes les d\u00E9marches aupr\u00E8s du Greffe du Tribunal des Entreprises et tout ce qui est n\u00E9cessaire \u00E0 ces fins.",
      "holder_kbo": null,
      "holder_name": "M. Koenraad Van der Elst",
      "scope_categories": [
        "publication",
        "filing",
        "KBO"
      ],
      "with_substitution": true
    },
    {
      "quote": "Le pr\u00E9sident soumet \u00E0 l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire la proposition d\u0027accorder des pouvoirs sp\u00E9ciaux \u00E0 M. Koenraad Van der Elst, Chief Legal Officer de la Soci\u00E9t\u00E9, et \u00E0 Mme. Gis\u00E8le Rosselle, M. C\u00E9deric Devroey, Mme. Marie-Elisabeth Dubois et M. Th\u00E9otime Liesenborghs, tous avocats au sein du cabinet Strelia, dont le si\u00E8ge est situ\u00E9 Rue Royale 145, 1000 Bruxelles, Belgique. Ces pouvoirs sp\u00E9ciaux permettent \u00E0 chacun d\u0027eux d\u0027agir individuellement et d\u0027avoir le pouvoir de subd\u00E9l\u00E9guer pour accomplir au nom et pour le compte de la Soci\u00E9t\u00E9 toutes les formalit\u00E9s relatives aux obligations de publicit\u00E9 impos\u00E9es par la loi concernant les r\u00E9solutions adopt\u00E9es lors de l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire et, plus particuli\u00E8rement, \u00E0 la publication d\u0027un extrait du pr\u00E9sent proc\u00E8s-verbal aux Annexes du Moniteur belge et, g\u00E9n\u00E9ralement, pour accomplir toutes les d\u00E9marches aupr\u00E8s du Greffe du Tribunal des Entreprises et tout ce qui est n\u00E9cessaire \u00E0 ces fins.",
      "holder_kbo": null,
      "holder_name": "Mme. Gis\u00E8le Rosselle",
      "scope_categories": [
        "publication",
        "filing",
        "KBO"
      ],
      "with_substitution": true
    },
    {
      "quote": "Le pr\u00E9sident soumet \u00E0 l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire la proposition d\u0027accorder des pouvoirs sp\u00E9ciaux \u00E0 M. Koenraad Van der Elst, Chief Legal Officer de la Soci\u00E9t\u00E9, et \u00E0 Mme. Gis\u00E8le Rosselle, M. C\u00E9deric Devroey, Mme. Marie-Elisabeth Dubois et M. Th\u00E9otime Liesenborghs, tous avocats au sein du cabinet Strelia, dont le si\u00E8ge est situ\u00E9 Rue Royale 145, 1000 Bruxelles, Belgique. Ces pouvoirs sp\u00E9ciaux permettent \u00E0 chacun d\u0027eux d\u0027agir individuellement et d\u0027avoir le pouvoir de subd\u00E9l\u00E9guer pour accomplir au nom et pour le compte de la Soci\u00E9t\u00E9 toutes les formalit\u00E9s relatives aux obligations de publicit\u00E9 impos\u00E9es par la loi concernant les r\u00E9solutions adopt\u00E9es lors de l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire et, plus particuli\u00E8rement, \u00E0 la publication d\u0027un extrait du pr\u00E9sent proc\u00E8s-verbal aux Annexes du Moniteur belge et, g\u00E9n\u00E9ralement, pour accomplir toutes les d\u00E9marches aupr\u00E8s du Greffe du Tribunal des Entreprises et tout ce qui est n\u00E9cessaire \u00E0 ces fins.",
      "holder_kbo": null,
      "holder_name": "M. C\u00E9deric Devroey",
      "scope_categories": [
        "publication",
        "filing",
        "KBO"
      ],
      "with_substitution": true
    },
    {
      "quote": "Le pr\u00E9sident soumet \u00E0 l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire la proposition d\u0027accorder des pouvoirs sp\u00E9ciaux \u00E0 M. Koenraad Van der Elst, Chief Legal Officer de la Soci\u00E9t\u00E9, et \u00E0 Mme. Gis\u00E8le Rosselle, M. C\u00E9deric Devroey, Mme. Marie-Elisabeth Dubois et M. Th\u00E9otime Liesenborghs, tous avocats au sein du cabinet Strelia, dont le si\u00E8ge est situ\u00E9 Rue Royale 145, 1000 Bruxelles, Belgique. Ces pouvoirs sp\u00E9ciaux permettent \u00E0 chacun d\u0027eux d\u0027agir individuellement et d\u0027avoir le pouvoir de subd\u00E9l\u00E9guer pour accomplir au nom et pour le compte de la Soci\u00E9t\u00E9 toutes les formalit\u00E9s relatives aux obligations de publicit\u00E9 impos\u00E9es par la loi concernant les r\u00E9solutions adopt\u00E9es lors de l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire et, plus particuli\u00E8rement, \u00E0 la publication d\u0027un extrait du pr\u00E9sent proc\u00E8s-verbal aux Annexes du Moniteur belge et, g\u00E9n\u00E9ralement, pour accomplir toutes les d\u00E9marches aupr\u00E8s du Greffe du Tribunal des Entreprises et tout ce qui est n\u00E9cessaire \u00E0 ces fins.",
      "holder_kbo": null,
      "holder_name": "Mme. Marie-Elisabeth Dubois",
      "scope_categories": [
        "publication",
        "filing",
        "KBO"
      ],
      "with_substitution": true
    },
    {
      "quote": "Le pr\u00E9sident soumet \u00E0 l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire la proposition d\u0027accorder des pouvoirs sp\u00E9ciaux \u00E0 M. Koenraad Van der Elst, Chief Legal Officer de la Soci\u00E9t\u00E9, et \u00E0 Mme. Gis\u00E8le Rosselle, M. C\u00E9deric Devroey, Mme. Marie-Elisabeth Dubois et M. Th\u00E9otime Liesenborghs, tous avocats au sein du cabinet Strelia, dont le si\u00E8ge est situ\u00E9 Rue Royale 145, 1000 Bruxelles, Belgique. Ces pouvoirs sp\u00E9ciaux permettent \u00E0 chacun d\u0027eux d\u0027agir individuellement et d\u0027avoir le pouvoir de subd\u00E9l\u00E9guer pour accomplir au nom et pour le compte de la Soci\u00E9t\u00E9 toutes les formalit\u00E9s relatives aux obligations de publicit\u00E9 impos\u00E9es par la loi concernant les r\u00E9solutions adopt\u00E9es lors de l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire et, plus particuli\u00E8rement, \u00E0 la publication d\u0027un extrait du pr\u00E9sent proc\u00E8s-verbal aux Annexes du Moniteur belge et, g\u00E9n\u00E9ralement, pour accomplir toutes les d\u00E9marches aupr\u00E8s du Greffe du Tribunal des Entreprises et tout ce qui est n\u00E9cessaire \u00E0 ces fins.",
      "holder_kbo": null,
      "holder_name": "M. Th\u00E9otime Liesenborghs",
      "scope_categories": [
        "publication",
        "filing",
        "KBO"
      ],
      "with_substitution": true
    },
    {
      "quote": "Le pr\u00E9sident soumet \u00E0 l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire la proposition d\u0027accorder des pouvoirs sp\u00E9ciaux \u00E0 M. Koenraad Van der Elst, Chief Legal Officer de la Soci\u00E9t\u00E9, et \u00E0 Mme. Gis\u00E8le Rosselle, M. C\u00E9deric Devroey, Mme. Marie-Elisabeth Dubois et M. Th\u00E9otime Liesenborghs, tous avocats au sein du cabinet Strelia, dont le si\u00E8ge est situ\u00E9 Rue Royale 145, 1000 Bruxelles, Belgique. Ces pouvoirs sp\u00E9ciaux permettent \u00E0 chacun d\u0027eux d\u0027agir individuellement et d\u0027avoir le pouvoir de subd\u00E9l\u00E9guer pour accomplir au nom et pour le compte de la Soci\u00E9t\u00E9 toutes les formalit\u00E9s relatives aux obligations de publicit\u00E9 impos\u00E9es par la loi concernant les r\u00E9solutions adopt\u00E9es lors de l\u2019Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire et, plus particuli\u00E8rement, \u00E0 la publication d\u0027un extrait du pr\u00E9sent proc\u00E8s-verbal aux Annexes du Moniteur belge et, g\u00E9n\u00E9ralement, pour accomplir toutes les d\u00E9marches aupr\u00E8s du Greffe du Tribunal des Entreprises et tout ce qui est n\u00E9cessaire \u00E0 ces fins.",
      "holder_kbo": null,
      "holder_name": "Strelia",
      "scope_categories": [
        "publication",
        "filing",
        "KBO"
      ],
      "with_substitution": true
    }
  ],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [
    {
      "kind": "commissaris_renew",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Olivier Declercq",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "KPMG Bedrijfsrevisoren BV / KPMG R\u00E9viseurs d\u0027Entreprises SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "L\u0027Assembl\u00E9e d\u00E9cide de nommer KPMG Bedrijfsrevisoren BV / KPMG R\u00E9viseurs d\u0027Entreprises SRL, repr\u00E9sent\u00E9e par Monsieur Declercq, en tant que commissaire de la Soci\u00E9t\u00E9 pour une dur\u00E9e de trois (3) ans prenant fin \u00E0 l\u0027issue de l\u0027assembl\u00E9e g\u00E9n\u00E9rale qui statuera sur l\u0027approbation des comptes annuels de l\u0027ex"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "statutaire",
      "new_address": {
        "city": "Li\u00E8ge",
        "region": null,
        "street": "Boulevard Patience et Beaujonc",
        "country": "BE",
        "postcode": "4000",
        "box_number": "1",
        "street_number": "3"
      },
      "old_address": {
        "city": "Li\u00E8ge",
        "region": null,
        "street": "Boulevard Gustave Kleyer",
        "country": "BE",
        "postcode": "4000",
        "box_number": null,
        "street_number": "17"
      },
      "effective_date": "2022-09-01",
      "evidence_quote": "le Conseil d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de transf\u00E9rer avec effet le 1 septembre 2022, le si\u00E8ge social de la Soci\u00E9t\u00E9 de 4000 Li\u00E8ge, Boulevard Gustave Kleyer 17 au Boulevard: Patience et Beaujonc N\u00B0 3/1, 4000 Li\u00E8ge."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "statutaire",
      "new_address": {
        "city": "Li\u00E8ge",
        "region": null,
        "street": "Boulevard Patience et Beaujonc",
        "country": "BE",
        "postcode": "4000",
        "box_number": "2",
        "street_number": "3"
      },
      "old_address": {
        "city": "Li\u00E8ge",
        "region": null,
        "street": "Boulevard Gustave Kleyer",
        "country": "BE",
        "postcode": "4000",
        "box_number": null,
        "street_number": "17"
      },
      "effective_date": "2022-09-01",
      "evidence_quote": "le Conseil d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de transf\u00E9rer avec effet le 1 septembre 2022, le si\u00E8ge social de la Soci\u00E9t\u00E9 de 4000 Li\u00E8ge, Boulevard Gustave Kleyer 17 au Boulevard Patience et Beaujonc N\u00B0 3/2, 4000 Li\u00E8ge."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 6000.0,
      "currency": "EUR",
      "after_eur": 140001.87,
      "delta_eur": 6000.0,
      "before_eur": 134001.87,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2022-06-22",
      "evidence_quote": "Le capital de la Soci\u00E9t\u00E9 a par cons\u00E9quent \u00E9t\u00E9 augment\u00E9 \u00E0 concurrence de 6.000,00 EUR et est effectivement port\u00E9 de 134.001,87 EUR \u00E0 140.001,87 EUR.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 15000001.0,
      "currency": "EUR",
      "after_eur": 134001.87,
      "delta_eur": 4838.71,
      "before_eur": 129163.16,
      "amount_type": "totale_inbreng",
      "effective_date": "2022-04-05",
      "evidence_quote": "Le capital de la Soci\u00E9t\u00E9 est par cons\u00E9quent port\u00E9 de 129.163,16 EUR \u00E0 134.001,87 EUR",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 25000.0,
      "currency": "EUR",
      "after_eur": null,
      "delta_eur": 25000.0,
      "before_eur": null,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2022-03-31",
      "evidence_quote": "Le conseil d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 dans le cadre du capital autoris\u00E9 ... par apport en num\u00E9raire pour un montant maximum de EUR 25.000,00 (hors prime d\u0027\u00E9mission)",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Chris Buyse",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "Pienter Jan BV",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "L\u0027Assembl\u00E9e d\u00E9cide d\u0027approuver la nomination de Pienter Jan BV ([...] ayant comme repr\u00E9sentant permanent M. Chris Buyse) en qualit\u00E9 d\u0027administrateur ind\u00E9pendant de la Soci\u00E9t\u00E9 pour une dur\u00E9e de quatre (4) ans jusqu\u0027\u00E0 la cl\u00F4ture de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire de 2025."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 86250000,
      "currency": "EUR",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "amount_type": "totale_inbreng",
      "effective_date": "2020-06-08",
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital par apport en num\u00E9raire moyennant une offre publique initiale de souscription \u00E0 concurrence d\u0027un montant maximal de 86,25 millions euros (prime d\u0027\u00E9mission incluse) par la cr\u00E9ation d\u0027actions nouvelles (l\u0027\u003C Offre \u00BB), telle que d\u00E9crite plus pr\u00E9cis\u00E9ment dans le Rapport du Conseil (7:179/7:180).",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 1200.0,
      "currency": "EUR",
      "after_eur": 129163.16,
      "delta_eur": 1200.0,
      "before_eur": 127963.16,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2020-07-31",
      "evidence_quote": "Le capital de la Soci\u00E9t\u00E9 a par cons\u00E9quent \u00E9t\u00E9 augment\u00E9 \u00E0 concurrence de 1.200,00 euros et effectivement port\u00E9 de 127.963,16 euros \u00E0 129.163,16? euros.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "stage": null,
  "notary": {
    "name": "Peter VAN MELKEBEKE",
    "firm_city": null,
    "firm_name": "Berquin Notaires",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2020-08-12",
    "filing_date": "2020-06-12",
    "act_kind_objet": "CONSTATATION (PARTIELLE) DE L\u0027EMISSION ET SOUSCRIPTION DE SOP"
  },
  "decision": {
    "body": "raad_van_bestuur",
    "act_date": "2020-06-16",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "other",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0674.494.151",
        "name": "Hyloris Pharmaceuticals",
        "role": "other",
        "address": "Boulevard Gustave Kleyer 17, 4000 Li\u00E8ge",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "5:121",
      "7:179",
      "7:180",
      "583"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "La division des actions existantes par un ratio de 4, entra\u00EEnant une augmentation du nombre total d\u0027actions de 4.450.442 \u00E0 17.801.768, avec une diminution proportionnelle de la valeur nominale comptable. Cette op\u00E9ration a des effets automatiques sur les instruments de capital (SOP Warrants, Obligations Convertibles, Transaction Warrants, Adjustment Warrants, Warrants Anti-dilutifs).",
    "equity_transferred_eur": null,
    "accounting_effective_date": null
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "Hyloris Pharmaceuticals",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": "0477.693.524",
    "org_name": "Herault",
    "person_name": null,
    "org_rep_person_name": "Koenraad Van der Elst"
  },
  "summary_narrative": "Le conseil d\u0027administration de Hyloris Pharmaceuticals a d\u00E9cid\u00E9, le 15 juin 2020, la division de ses actions par un ratio de 4, ce qui a port\u00E9 le nombre total d\u0027actions de 4.450.442 \u00E0 17.801.768. Cette op\u00E9ration a entra\u00EEn\u00E9 des ajustements automatiques sur divers instruments de capital, notamment les SOP Warrants, les Obligations Convertibles, les Transaction Warrants, les Adjustment Warrants et les Warrants Anti-dilutifs. Les statuts ont \u00E9t\u00E9 modifi\u00E9s pour refl\u00E9ter le nouveau capital et le nouveau nombre d\u0027actions.",
  "co_filed_documents": [
    "une exp\u00E9dition du proc\u00E8s-verbal du huit juin deux mille vingt",
    "une exp\u00E9dition du proc\u00E8s-verbal du seize juin deux mille vingt"
  ],
  "detected_real_type": "other",
  "referenced_correction": null,
  "should_reroute_to_category": "statutes"
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 28750,
      "currency": "EUR",
      "after_eur": 117758.84,
      "delta_eur": 28750.0,
      "before_eur": 89008.84,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2020-06-30",
      "evidence_quote": "L\u0027augmentation de capital par apport en num\u00E9raire moyennant une offre publique initiale de souscription qui pr\u00E9c\u00E8de est effectivement r\u00E9alis\u00E9e \u00E0 concurrence de 28.750 EUR (prime d\u0027\u00E9mission exclue) et qu\u0027ainsi le capital est effectivement port\u00E9 \u00E0 117.758,84 EUR",
      "contribution_type": "cash"
    },
    {
      "kind": "capital_increase",
      "amount": 10204.32,
      "currency": "EUR",
      "after_eur": 127963.16,
      "delta_eur": 10204.32,
      "before_eur": 117758.84,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2020-06-30",
      "evidence_quote": "Le capital a \u00E9t\u00E9 augment\u00E9 \u00E0 concurrence de 10.204,32 EUR et est port\u00E9 de 117.758,84 EUR \u00E0 127.963,16 EUR.",
      "contribution_type": "in_kind"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": true,
    "effective_date": "2020-03-31",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  },
  "signature_regime": "joint_two",
  "special_mandates": [
    {
      "quote": "L\u0027assembl\u00E9e d\u00E9cide de donner procuration \u00E0 chaque administrateur et au CEO, CFO et CLO (actuellement la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e \u0022 Herault \u0022, ayant son si\u00E8ge \u00E0 Vijfhoekweg 13, 3150 Haacht, avec num\u00E9ro d\u0027entreprise 0477.693.524) de la soci\u00E9t\u00E9 ainsi que, compte tenu des mesures prises r\u00E9cemment par le gouvernement belge dans le cadre de la pand\u00E9mie de maladie \u00E0 coronavirus (COVID-19), \u00E0 Joeri PIESSENS, Sarah NiJS et tout autre collaborateur du cabinet Berquin Notaires, avec pouvoir d\u0027agir individuellement et de se faire remplacer, pour r\u00E9aliser la souscription et l\u0027\u00E9mission d\u0027Obligations Convertibles.",
      "holder_kbo": "0477.693.524",
      "holder_name": "Herault",
      "scope_categories": [
        "issuance",
        "subscription",
        "banking",
        "notarial",
        "filing"
      ],
      "with_substitution": true
    },
    {
      "quote": "L\u0027assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Luana Huybrechts, Michiel Stuyts, Joris De Wolf et tout autre avocat ou collaborateur du cabinet d\u0027avocats Eubelius SCRL, \u00E0 1050 Bruxelles, Avenue louise 99, chacun agissant s\u00E9par\u00E9ment, ainsi qu\u0027\u00E0 leurs employ\u00E9s, pr\u00E9pos\u00E9s et mandataires, avec droit de substitution, afin d\u0027assurer les formalit\u00E9s aupr\u00E8s d\u0027un guichet d\u0027entreprise en vue d\u0027assurer l\u0027inscription/la modification des donn\u00E9es dans la Banque Carrefour des Entreprises et, le cas \u00E9ch\u00E9ant, aupr\u00E8s de l\u0027Administration de la Taxe sur la Valeur Ajout\u00E9e.",
      "holder_kbo": null,
      "holder_name": "Eubelius SCRL",
      "scope_categories": [
        "KBO",
        "tax",
        "filing"
      ],
      "with_substitution": true
    }
  ],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2019-12-31",
    "legal_form_change": false
  },
  "bedrijfsrevisor": {
    "quote": "L\u0027assembl\u00E9e d\u00E9cide de nommer la soci\u00E9t\u00E9 coop\u00E9rative \u00E0 responsabilit\u00E9 limit\u00E9e \u0022 KPMG R\u00E9viseurs d\u0027Entreprises \u0022, \u00E9tablie \u00E0 1930 Zaventem, A\u00E9roport Bruxelles National 1K, en tant que commissaire pour un mandat d\u0027une dur\u00E9e de trois ans. [...] La soci\u00E9t\u00E9 coop\u00E9rative \u00E0 responsabilit\u00E9 limit\u00E9e \u0022KPMG R\u00E9viseurs d\u0027Entreprises\u0022 d\u00E9signe monsieur Olivier DECLERCQ (IRE Nr. A02076), r\u00E9viseur d\u0027entreprises, comme repr\u00E9sentant permanent.",
    "firm_kbo": null,
    "firm_name": "KPMG R\u00E9viseurs d\u0027Entreprises",
    "ibr_number": "A02076",
    "individual_name": "Olivier DECLERCQ"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  },
  "signature_regime": "joint_two",
  "special_mandates": [
    {
      "quote": "L\u0027assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Michiel Stuyts, Joris De Wolf et tout autre avocat ou collaborateur du cabinet d\u0027avocats Eubelius SCRL, \u00E0 1050 Bruxelles, Avenue louise 99, chacun agissant s\u00E9par\u00E9ment, ainsi qu\u0027\u00E0 leurs employ\u00E9s, pr\u00E9pos\u00E9s et mandataires, avec droit de substitution, afin d\u0027assurer les formalit\u00E9s aupr\u00E8s d\u0027un guichet d\u0027entreprise en vue d\u0027assurer l\u0027inscription/la modification des donn\u00E9es dans la Banque Carrefour des Entreprises et, le cas \u00E9ch\u00E9ant, aupr\u00E8s de l\u0027Administration de la Taxe sur la Valeur Ajout\u00E9e.",
      "holder_kbo": null,
      "holder_name": "Eubelius SCRL",
      "scope_categories": [
        "KBO",
        "tax",
        "filing"
      ],
      "with_substitution": true
    }
  ],
  "governance_change": {
    "admin_delegated_added": [
      {
        "name": "SVR Management",
        "quote": "La soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e \u0022 SVR Management \u0022 a d\u00E9sign\u00E9 Monsieur Stijn VAN ROMPAY, pr\u00E9nomm\u00E9, en tant que repr\u00E9sentant permanent. Compte tenu du fait que la soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e \u0022 SVR Management \u0022 est \u00E9galement d\u00E9l\u00E9gu\u00E9e \u00E0 la gestion journali\u00E8re de la Soci\u00E9t\u00E9, elle portera le titre d\u0027administrateur d\u00E9l\u00E9gu\u00E9.",
        "excluded_powers": null
      }
    ]
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "dagelijks_bestuur",
      "person": {
        "rrn": null,
        "name": "Stijn Van Rompay",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "SVR Management BVBA",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2019-12-31",
      "evidence_quote": "SVR Management BVBA, met vertegenwoordiger permanent Stijn Van Rompay, is gedelegeerd bestuurder (en bestuurder gedelegeerd) (ter vervanging van SVR Invest BVBA, met vertegenwoordiger permanent Stijn Van Rompayen) sinds 31 december 2019."
    },
    {
      "kind": "director_out",
      "role": "dagelijks_bestuur",
      "person": {
        "rrn": null,
        "name": "Stijn Van Rompayen",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "SVR Invest BVBA",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2019-12-31",
      "evidence_quote": "SVR Management BVBA vervangt SVR Invest BVBA als gedelegeerd bestuurder (en bestuurder gedelegeerd)."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "statutaire",
      "new_address": {
        "city": "Li\u00E8ge",
        "region": null,
        "street": "Boulevard Gustave Kleyer",
        "country": "BE",
        "postcode": "4000",
        "box_number": null,
        "street_number": "17"
      },
      "old_address": {
        "city": "Li\u00E8ge",
        "region": null,
        "street": "Avenue Hippocrate",
        "country": "BE",
        "postcode": "4000",
        "box_number": null,
        "street_number": "5"
      },
      "effective_date": "2019-02-06",
      "evidence_quote": "le Conseil d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de transf\u00E9rer avec effet imm\u00E9diat le si\u00E8ge social de la Soci\u00E9t\u00E9 de 4000 Li\u00E8ge, Avenue Hippocrate 5 \u00E0 4000 Li\u00E8ge, Boulevard Gustave Kleyer 17."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2018-05-31",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  },
  "signature_regime": null,
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 4974.22,
      "currency": "EUR",
      "after_eur": 66474.22,
      "delta_eur": 4974.22,
      "before_eur": 61500.0,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2018-05-31",
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 \u00E0 concurrence de quatre mille neuf cent septante-quatre euros vingt-deux cents (4.974,22 EUR), pour le porter de soixante et un mille cinq cents euros (61.500,00 EUR) \u00E0 soixante-six mille quatre cent septante-quatre euros vingt-deux cents (66.474,22 EUR).",
      "contribution_type": "cash"
    },
    {
      "kind": "capital_increase",
      "amount": 2745025.78,
      "currency": "EUR",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "amount_type": "uitgiftepremie",
      "effective_date": "2018-05-31",
      "evidence_quote": "11,0369 EUR (arrondis) par action seront comptabilis\u00E9s sur un compte \u0022Primes d\u0027\u00E9mission\u0022, soit au total de deux millions sept cent quarante-cinq mille vingt-cing euros septante-huit cents (2.745.025,78 EUR).",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "gedelegeerd_bestuurder",
      "person": {
        "rrn": null,
        "name": "Stijn Van Rompay",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0479774371",
        "name": "SVR Invest",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2017-04-05",
      "evidence_quote": "Le conseil d\u0027administration d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de nommer la soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e SVR Invest, ayant son si\u00E8ge social \u00E0 Square Marie Curie 50, 1070 Anderlecht, inscrite aupr\u00E8s du Reg\u00EDstre des personnes morales sous le num\u00E9ro 479.774.371, repr\u00E9sent\u00E9e de fa\u00E7on permanente par Monsieu"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 61500.0,
      "currency": "EUR",
      "after_eur": 61500.0,
      "delta_eur": 0.0,
      "before_eur": 61500.0,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2017-05-12",
      "evidence_quote": "Le capital souscrit est fix\u00E9 \u00E0 soixante et un mille cing cent euro (61.500,00 EUR).",
      "contribution_type": "cash"
    },
    {
      "kind": "capital_increase",
      "amount": null,
      "currency": "EUR",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": 61500.0,
      "amount_type": "kapitaal_toegestaan",
      "effective_date": "2017-05-12",
      "evidence_quote": "d\u0027augmenter le capital \u00E0 concurrence d\u0027une somme maximale \u00E9quivalente \u00E0 la multiplication du nombre de warrants attribu\u00E9s et exerc\u00E9s par le prix d\u0027exercice de ces warrants... par la cr\u00E9ation de maximum trois cents mille (300.000) nouvelles actions",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "zaakvoerder",
      "person": {
        "rrn": null,
        "name": "Stijn Van Rompay",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0479774371",
        "name": "SVR Invest",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2017-04-24",
      "evidence_quote": "Le conseil d\u0027administration d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de nommer la soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e SVR Invest, ayant son si\u00E8ge social \u00E0 Square Marie Curie 50, 1070 Anderlecht, inscrite aupr\u00E8s du Registre des personnes morales sous le num\u00E9ro 479.774.371, repr\u00E9sent\u00E9e de fa\u00E7on permanente par Monsieu"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.494.151",
    "name_full": "HYLORIS PHARMACEUTICALS, EN ABREGE : HYLORIS",
    "legal_form": "SA"
  }
}